| Allyl isothiocyanate (AITC) — a small, highly reactive organosulfur isothiocyanate and electrophilic phytochemical generated principally by myrosinase-mediated hydrolysis of the glucosinolate sinigrin. It is classified as a natural-product compound within the isothiocyanate class; synonyms include allyl mustard oil, volatile mustard oil, and 2-propenyl isothiocyanate. Major dietary sources include brown/black mustard, horseradish, wasabi, cabbage, Brussels sprouts, and other Brassicaceae containing sinigrin. AITC reacts readily with cellular thiols, particularly glutathione and cysteine residues of proteins, which underlies both its rapid metabolism and many of its biological effects. Isothiocyanates is the parent class.
Primary mechanisms (ranked):
- Electrophilic thiol reactivity and glutathione conjugation produce redox stress; in susceptible cancer cells, depletion of reduced glutathione and increased ROS contribute to cell-cycle arrest and apoptosis.
- Direct covalent modification of tubulin cysteine residues promotes α/β-tubulin ubiquitination and degradation, disrupts mitosis, and produces profound G2/M or mitotic arrest.
- Mitotic and oxidative stress activate JNK/BCL-2 signaling and mitochondrial apoptosis, including mitochondrial membrane depolarization, cytochrome-c release, and caspase-9/-3 activation.
- ROS and intracellular Ca²⁺ perturbation activate endoplasmic-reticulum stress pathways including calpain, ATF6, GRP78/GRP94, CHOP/GADD153, and caspase-4.
- NRF2 signaling is strongly context- and dose-dependent: lower exposures can activate NRF2-dependent antioxidant and p21 programs, whereas higher cytotoxic exposures may overwhelm antioxidant capacity or suppress NRF2-associated defenses in some cancer models.
- AITC can induce DNA damage responses and alter DNA-repair machinery, including ATM/ATR, γH2AX, p53/p21, DNA-PK, MGMT, and related checkpoint proteins.
- Suppression of oncogenic inflammatory, angiogenic, and invasive signaling includes EGFR/JAK1/STAT3, NF-κB, VEGF, TNF-α, inflammatory cytokines, and MMP-2/-9 in model-dependent settings.
- AITC can act as a chemosensitizer, particularly with cisplatin in preclinical models, through prolonged G2/M disruption, tubulin depletion, suppression of checkpoint proteins, BCL-2, and survivin.
Bioavailability / PK relevance: Oral absorption is high, historically estimated near 90%, but free AITC is highly reactive and rapidly conjugated through the glutathione/mercapturic-acid pathway to AITC-GSH, cysteine conjugates, and especially urinary NAC-AITC. Human mustard-feeding studies demonstrate rapid urinary appearance, with most NAC-AITC excretion occurring within approximately 8 hours and little detected after 12 hours. Urinary exposure greatly exceeds plasma exposure, providing a particularly favorable pharmacokinetic rationale for bladder-directed chemoprevention or treatment. Food preparation is important because destruction of plant myrosinase by extensive cooking can reduce formation of AITC from sinigrin.
In-vitro vs systemic exposure relevance: Many direct cytotoxic cancer experiments use approximately low-to-tens of micromolar AITC, commonly around 5–30 µM. Sustained free-AITC concentrations of this magnitude should not be assumed to occur systemically after dietary intake because AITC is rapidly conjugated and cleared. The urinary tract is a notable exception: AITC equivalents and bioactive mercapturic-acid metabolites become strongly concentrated in urine, and animal bladder-tumor tissue exposure can greatly exceed plasma and non-bladder tissues. Consequently, bladder-cancer models have substantially stronger PK plausibility than many systemic in-vitro models.
Clinical evidence status: Preclinical for cancer treatment. There are extensive cell-culture studies and multiple animal tumor models, including bladder, colorectal, oral, glioblastoma, breast/mammary, and other cancers. Small human dietary intervention studies demonstrate absorption, metabolism, biomarker modulation, and short-term cytoprotective effects from AITC-containing mustard, but there is no established randomized human oncology trial demonstrating tumor response, progression benefit, or survival benefit from AITC. It is therefore not an established anticancer drug or oncology adjunct. AITC is permitted as a food flavouring substance in the United States under 21 CFR 172.515, but this regulatory status does not imply therapeutic approval. AITC is a potent TRPA1 agonist and irritant; concentrated exposure can cause burning pain and neurogenic inflammation. Toxicological assessment also warrants caution with pharmacological chronic dosing, particularly because high-dose animal studies have identified urinary-bladder epithelial toxicity.
AITC Mechanistic Profile
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
Primary Effect |
Notes / Interpretation |
| 1 |
GSH depletion and ROS stress |
↓ GSH; ↑ ROS; ↑ oxidative stress; ↑ apoptosis |
↑ NRF2-dependent antioxidant response at lower exposure; cytotoxicity possible at high exposure |
Redox-dependent cytotoxicity |
AITC rapidly conjugates with GSH. Recent HepG2 work directly links intracellular AITC-GSH formation, loss of reduced GSH, ROS accumulation, G2/M arrest, and apoptosis. ROS inhibition can reverse the cell-cycle effect. |
| 2 |
Tubulin and mitotic machinery |
↓ α-tubulin; ↓ β-tubulin; ↑ tubulin ubiquitination; ↑ G2/M arrest |
Less cytotoxic in normal bladder epithelium (model-dependent) |
Mitotic arrest |
AITC directly modifies cysteine residues on tubulin and promotes tubulin degradation. This is one of the best-defined direct molecular mechanisms of AITC. |
| 3 |
JNK BCL-2 mitochondrial apoptosis |
↑ JNK; ↑ BCL-2 Ser70 phosphorylation; ↓ mitochondrial potential; ↑ cytochrome c; ↑ caspase-9/-3 |
↔ or lower activation at comparable exposure (model-dependent) |
Intrinsic apoptosis |
In bladder-cancer models, apoptosis follows mitotic arrest and depends strongly on JNK-mediated BCL-2 phosphorylation and mitochondrial caspase signaling. |
| 4 |
ER stress and Ca²⁺ signaling |
↑ cytosolic Ca²⁺; ↑ calpain; ↑ ATF6; ↑ GRP78/GRP94; ↑ CHOP; ↑ caspase-4 |
Context-dependent stress response |
ER-stress-mediated apoptosis |
Demonstrated prominently in colorectal cancer cells and mechanistically linked to ROS generation and mitochondrial apoptosis. |
| 5 |
NRF2 p21 antioxidant checkpoint |
↑ NRF2 and ↑ p21 at lower exposure; mixed or impaired antioxidant response at higher exposure |
↑ NRF2; ↑ HO-1; ↑ NQO1; ↑ glutathione synthesis enzymes |
Antioxidant defense and cell-cycle control |
Strongly dose-dependent. Low-dose NRF2 activation can participate in growth suppression through p21, whereas high cytotoxic exposure can overwhelm or suppress antioxidant capacity. NRF2 should therefore not be classified simply as increased or decreased. |
| 6 |
DNA damage and repair checkpoints |
↑ γH2AX; ↑ ATM/ATR signaling; ↑ p53/p21; altered DNA-PK and MGMT |
Not adequately characterized for cancer selectivity |
DNA damage and checkpoint activation |
Observed in breast and gastric cancer cells, generally at micromolar exposures. The exact repair-protein pattern varies by cell type. |
| 7 |
EGFR JAK1 STAT3 signaling |
↓ EGFR-associated signaling; ↓ JAK1/STAT3 activity |
Context-dependent |
↓ proliferation, invasion, and angiogenesis |
Supported in mammary tumor models; relevant principally as an invasion and progression mechanism rather than the primary acute cytotoxic mechanism. |
| 8 |
VEGF inflammatory angiogenic signaling |
↓ VEGF; ↓ TNF-α; ↓ IL-1β; ↓ IL-6; ↓ NO signaling |
↓ inflammatory signaling; ↑ NRF2 responses in some normal-cell models |
Antiangiogenic and anti-inflammatory activity |
AITC inhibits endothelial proliferation, migration, invasion, and tube formation in preclinical systems. |
| 9 |
MMP invasion and metastasis |
↓ MMP-2; ↓ MMP-9; ↓ migration; ↓ invasion |
Limited data |
Antimetastatic activity |
Both AITC and its urinary NAC conjugate show activity, indicating that metabolism does not necessarily abolish biological activity. |
| 10 |
Cisplatin chemosensitization |
↓ β-tubulin; ↓ CDC2; ↓ cyclin B1; ↓ CDC25; ↓ BCL-2; ↓ survivin; ↑ apoptosis |
No clear increase in systemic toxicity in reported animal combination models |
↑ cisplatin sensitivity |
Preclinical combination studies show synergistic growth inhibition and prolonged G2/M disruption, but this has not been validated as a human oncology regimen. |
| 11 |
Clinical Translation Constraint |
Micromolar cytotoxicity achievable most plausibly in urinary tract exposure |
High concentrated exposure is irritant and can damage normal tissues |
Limits systemic therapeutic extrapolation |
Rapid GSH conjugation and mercapturic-acid metabolism limit sustained free systemic AITC. Urinary concentration creates an important bladder-specific PK advantage. Human cancer efficacy trials are lacking, and chronic pharmacological dosing is not established. |
|